Janux Therapeutics, Inc. (JANX)
NASDAQ: JANX · Real-Time Price · USD
56.83
+0.08 (0.14%)
Dec 20, 2024, 4:00 PM EST - Market closed
Janux Therapeutics Employees
Janux Therapeutics had 64 employees as of December 31, 2023. The number of employees increased by 4 or 6.67% compared to the previous year.
Employees
64
Change (1Y)
4
Growth (1Y)
6.67%
Revenue / Employee
$203,891
Profits / Employee
-$945,875
Market Cap
2.98B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 64 | 4 | 6.67% |
| Dec 31, 2022 | 60 | 27 | 81.82% |
| Dec 31, 2021 | 33 | 21 | 175.00% |
| Dec 31, 2020 | 12 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| BrightSpring Health Services | 35,000 |
| Envista Holdings | 12,800 |
| Warby Parker | 3,473 |
| Inari Medical | 1,300 |
| Veracyte | 815 |
| Amicus Therapeutics | 517 |
| Denali Therapeutics | 445 |
| Xenon Pharmaceuticals | 259 |
JANX News
- 15 days ago - Janux Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Pre-Funded Warrants Including Full Exercise of Underwriters' Option to Purchase Additional Shares for Total Gross Proceeds of $402.5 Million - Business Wire
- 17 days ago - Janux Therapeutics Announces Pricing of $350.0 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants - Business Wire
- 18 days ago - Janux Therapeutics Announces Proposed Public Offering - Business Wire
- 18 days ago - Janux Therapeutics' Prostate Cancer Trial Data Exceeds Investor Expectations: Analyst - Benzinga
- 18 days ago - Janux Therapeutics Stock Soars 70% on Prostate Cancer Drug Trial Results - Barrons
- 19 days ago - Janux Announces Doses Selected for Phase 1b Expansion Trials Supported by Encouraging Efficacy and Safety Profile Observed in Phase 1a Dose Escalation for JANX007 in mCRPC - Business Wire
- 26 days ago - Janux Therapeutics to Host Virtual Event Discussing Updated Clinical Data in Phase 1a Dose Escalation for JANX007 in mCRPC and Doses Selected for Phase 1b Expansion Studies - Business Wire
- 4 weeks ago - Janux Therapeutics: Believable Theory, Strong Early Data, Needs Confirmation - Seeking Alpha